Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Oppenheimer Cuts Price Target on Alexion Pharma (ALXN) Following Data Release
June 7, 2016 9:46 AM EDTOppenheimer maintained an Outperform rating on Alexion Pharmaceuticals (NASDAQ: ALXN), and cut the price target to $221.00 (from $228.00), following the company's announced top-line data from Phase 3 REGAIN study of eculizumab (Soliris) in refractory generalized myasthenia gravis (rGMG).
Analyst Christopher Marai commented, "Alexion announced... More
Alexion Pharma (ALXN): MG P3 Miss Increases Importance of ALXN-1210; PT to $160 - BMO
June 7, 2016 6:18 AM EDTBMO Capital analyst, Ian Somaiya, cut his price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $160 from $168 following disappointing data from the Phase III trial of Soliris in Myasthenia Gravis (MG). Although the totality of the data suggests significant benefit, the study missed its primary endpoint... More
Alexion Pharma (ALXN) Sinks 9% as Trading Resumes
June 6, 2016 4:35 PM EDTAlexion Pharma (NASDAQ: ALXN) has resumed trading and is down 8.9% after Phase 3 REGAIN study of Eculizumab did not reach statistical significance.
... MoreAlexion Pharma (ALXN) to Resume Trading at 4:30PM Following Trial Failure
June 6, 2016 4:14 PM EDTAlexion Pharma (NASDAQ: ALXN) to resume trading at 4:30PM ET after Phase 3 REGAIN Study of Eculizumab did not reach statistical significance.
... More